Skip to main content

The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study.

Publication ,  Journal Article
DiChiara, J; Bliden, KP; Tantry, US; Hamed, MS; Antonino, MJ; Suarez, TA; Bailon, O; Singla, A; Gurbel, PA
Published in: Diabetes
December 2007

OBJECTIVE: Diabetic patients may have a higher prevalence of platelet aspirin resistance than nondiabetic patients. Our goal was to analyze platelet aspirin responsiveness to various aspirin doses in diabetic and nondiabetic patients. RESEARCH DESIGN AND METHODS: We examined the effect of aspirin (81, 162, and 325 mg/day for 4 weeks each) on platelet aspirin responsiveness in 120 stable outpatients (30 diabetic patients and 90 nondiabetic patients) with coronary artery disease (CAD) using light transmittance aggregometry (LTA), VerifyNow, platelet function analyzer (PFA)-100, and levels of urinary 11-dehydro-thromboxane B(2) (11-dh-TxB(2)). RESULTS: In the total group, a low prevalence (0-2%) of aspirin resistance was observed with all aspirin doses as determined by arachidonic acid-induced LTA. Aspirin resistance was higher at the 81-mg dose in diabetic versus nondiabetic patients using collagen-induced LTA (27 vs. 4%, P = 0.001), VerifyNow (13 vs. 3%, P = 0.05), and urinary 11-dh-TxB(2) (37 vs. 17%, P = 0.03). Diabetic patients treated with 81 mg exhibited higher platelet function measured by VerifyNow, collagen- and ADP-induced LTA, and 11-dh-TxB(2) levels (P

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Diabetes

DOI

EISSN

1939-327X

Publication Date

December 2007

Volume

56

Issue

12

Start / End Page

3014 / 3019

Location

United States

Related Subject Headings

  • Thromboxane B2
  • Reference Values
  • Platelet Aggregation Inhibitors
  • Platelet Aggregation
  • Middle Aged
  • Male
  • Humans
  • Female
  • Endocrinology & Metabolism
  • Drug Resistance
 

Citation

APA
Chicago
ICMJE
MLA
NLM
DiChiara, J., Bliden, K. P., Tantry, U. S., Hamed, M. S., Antonino, M. J., Suarez, T. A., … Gurbel, P. A. (2007). The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes, 56(12), 3014–3019. https://doi.org/10.2337/db07-0707
DiChiara, Joseph, Kevin P. Bliden, Udaya S. Tantry, Miruais S. Hamed, Mark J. Antonino, Thomas A. Suarez, Oscar Bailon, Anand Singla, and Paul A. Gurbel. “The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study.Diabetes 56, no. 12 (December 2007): 3014–19. https://doi.org/10.2337/db07-0707.
DiChiara J, Bliden KP, Tantry US, Hamed MS, Antonino MJ, Suarez TA, et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes. 2007 Dec;56(12):3014–9.
DiChiara, Joseph, et al. “The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study.Diabetes, vol. 56, no. 12, Dec. 2007, pp. 3014–19. Pubmed, doi:10.2337/db07-0707.
DiChiara J, Bliden KP, Tantry US, Hamed MS, Antonino MJ, Suarez TA, Bailon O, Singla A, Gurbel PA. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes. 2007 Dec;56(12):3014–3019.

Published In

Diabetes

DOI

EISSN

1939-327X

Publication Date

December 2007

Volume

56

Issue

12

Start / End Page

3014 / 3019

Location

United States

Related Subject Headings

  • Thromboxane B2
  • Reference Values
  • Platelet Aggregation Inhibitors
  • Platelet Aggregation
  • Middle Aged
  • Male
  • Humans
  • Female
  • Endocrinology & Metabolism
  • Drug Resistance